Pune, India, July 26, 2019 (GLOBE NEWSWIRE) -- The Global Non-Alcoholic Steatohepatitis Biomarkers Market Is Anticipated To Garner A Market Revenue Of USD 1,960.4 Million, At 20.92% CAGR In The Forecast Period Of 2019-2024, published by Market Research Future
Non-Alcoholic Steatohepatitis Biomarkers Market is a non-alcoholic fatty liver disease where the liver is significantly damaged due to a buildup of fat in it. Presently, there is no single approved diagnosis test for non-alcoholic steatohepatitis. Biomarkers are referred to as an indicator used to measure the severity of or the presence of a disease. Hence, non-alcoholic steatohepatitis (NASH) biomarkers are used to measure the severity and occurrence of liver inflammation caused because of fat deposition in the liver.
The global non-alcoholic steatohepatitis biomarkers market is anticipated to grow owing to a mounting prevalence of NASH and a growing demand for minimally invasive treatments & diagnostic tests. Rising number of initiatives to create awareness regarding the disease is also contributing to the ascension of the market. Data released by NASH Education Program, a 63% rise in the prevalence of non-alcoholic steatohepatitis is expected between 2015-2023.
Fill Out Details To Receive Free Sample Here @ https://www.marketresearchfuture.com/sample_request/7984
Another factor attributable to the ascending NASH biomarkers market includes a magnified prevalence of diabetes and obesity. However, strict government regulations by the FDA for biomarkers qualification is likely to hinder market growth through the forecast period.
Key Players
Some prominent players in the global non-alcoholic steatohepatitis (NASH) biomarkers market include BioPredictive (France), Celerion (US), Cisbio (France), Echosens (France), Enterome (France), GENFIT (France), Laboratory Corporation of America Holdings (US), NGM Biopharmaceuticals (US), One Way Liver, SL (Spain), Pacific Biomarkers (US), Prometheus Laboratories Inc (US), Perspectrum Diagnostics Ltd (UK), Quest Diagnostics, Regulus Therapeutics, Inc. (US), Siemens Healthineers (Germany), Shenzhen New Industries Biomedical Engineering Co., Ltd (China), and Xeptagen SpA (Italy).
Industry Update
June 2019: High Joint Clinical Trials Center recently announced a 3-year collaboration with ProSciento as a site partner for NASH PASS. NASH PASS is a program by Prosciento which combines select qualified sites and proprietary methodology to enhance enrollment outcomes in nonalcoholic steatohepatitis clinical trials.
June 2019: DILIsym recently announced its release of NAFLDsym, which is a quantitative systems pharmacology (QSP) modeling software to support the development of various treatments for non-alcoholic fatty liver disease/ non-alcoholic steatohepatitis.
Market Segmentation
The Global Non-Alcoholic Steatohepatitis Biomarkers Market is segmented on the basis of type, end-users, and region. Based on type, the global non-alcoholic steatohepatitis (NASH) biomarkers market is segmented into serum biomarkers, apoptosis biomarkers, hepatic fibrosis biomarkers, and oxidative stress biomarkers. Based on end-users, the global non-alcoholic steatohepatitis (NASH) biomarkers market is segmented into research institutes & academics, pharmaceutical companies & CROs, hospitals & clinics, and diagnostic centers.
The Americas to Spearhead Global Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market by 2024
The global non-alcoholic steatohepatitis (NASH) biomarkers market has been studied by Non-Alcoholic Steatohepatitis Biomarkers Market Research Future (MRFR) for the regional segments of the Americas, Asia Pacific, Europe, and the Middle East & Africa. The Americas are further sub-segmented into North America and South America. The Americas are expected to dictate the global non-alcoholic steatohepatitis (NASH) biomarkers market over the forecast period of 2018-2024. Growth in this region is credible to favorable government initiatives and the presence of sophisticated healthcare infrastructure.
Further, rising prevalence of diabetes, fatty liver disease, and obesity are likely to contribute to the sizeable growth of the non-alcoholic steatohepatitis (NASH) biomarkers market. Moreover, in the recent past, several public health groups and government health organizations have taken various steps to create awareness towards the disease, snowballing market growth for the same. Further, they have also published new and updated guidelines for better management of non-alcoholic fatty liver disease/ non-alcoholic steatohepatitis.
Browse the market data and information spread across 111 pages with 69 data tables and 25 figures of the report “Non-Alcoholic Steatohepatitis Biomarkers Market - Forecast 2019-2024” in-depth alongside table of content (TOC) at https://www.marketresearchfuture.com/reports/non-alcoholic-steatohepatitis-biomarkers-market-7984
Europe is assessed to be the second largest market for non-alcoholic steatohepatitis (NASH) biomarkers during the assessment period, following the Americas. Proliferating prevalence of non-alcoholic steatohepatitis (NASH), diabetes, and obesity are influencing positive growth in the regional NASH biomarkers market. Further, the presence of a well-developed healthcare sector and increasing research and development activities towards liver diseases are anticipated to drive the non-alcoholic steatohepatitis biomarkers market in the region.
Asia Pacific is projected to attain significant growth rates in the non-alcoholic steatohepatitis biomarkers market over the forecast period. Such growth can be accredited to the presence of a huge patient population and an ascension in the healthcare expenditure by 2024. Further, better availability of healthcare personnel in the region is likely to magnify growth in the region’s non-alcoholic steatohepatitis (NASH) biomarkers market over the review period. Within the APAC, Australia accounted for 5.7% share at the beginning of the review period.
The Middle East & Africa is projected to garner the smallest share in the global NASH biomarkers market. Within Africa, the non-alcoholic steatohepatitis (NASH) biomarkers market is anticipated to face substantial hindrance owing to poor healthcare infrastructure, lower disposable income due to substandard economic conditions and lack of awareness towards liver diseases.
For Enquiry OR Any Query? Ask To Our Expert @ https://www.marketresearchfuture.com/enquiry/7984
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.